Pancreatic Cancer Diagnostics Market to be dominated by Diagnostic Imaging Tests through 2028
Increasing
incidence of pancreatic cancer, and rising demand for minimally invasive
diagnostic procedures are expected to drive the growth of Global Pancreatic
Cancer Diagnostics Market in the forecast period.
According to TechSci Research report, “Pancreatic Cancer
Diagnostics Market –Global Industry Size, Share, Trends, Opportunity,
and Forecast, 2018-2028,” the Global Pancreatic Cancer
Diagnostics Market is expected to grow during the forecast period, 2024-2028.
This can be ascribed to the increasing incidence of pancreatic cancer, rising
demand for minimally invasive diagnostic procedures, and growing investment in
research and development.
The COVID-19 pandemic has had a significant impact on the global
healthcare industry, including the market for pancreatic cancer diagnostics.
While the pandemic has led to increased demand for COVID-19 testing, it has
also disrupted routine healthcare services, including cancer screening and
diagnostic procedures. The market for pancreatic cancer diagnostics has been
particularly affected by the pandemic. As hospitals and healthcare facilities
focus on treating COVID-19 patients, many elective procedures, including cancer
screening and diagnostic tests, have been postponed or canceled. This has led
to a decline in demand for pancreatic cancer diagnostic tests, as patients are
unable or unwilling to undergo these procedures during the pandemic.
There are some challenges that are hampering the growth of global pancreatic
cancer diagnostics market in the forecast period. These challenges include the
lack of early symptoms, limited diagnostic tools, lack of reliable biomarkers,
difficulty in distinguishing between pancreatic cancer and other pancreatic
conditions, and the limited effectiveness of current treatment options.
Browse over XX market
data Figures spread through XX Pages and an in-depth TOC on "Global Pancreatic Cancer Diagnostics Market.”
Global Pancreatic
Cancer Diagnostics Market
can be segmented by test type, by cancer type, by end user, by region and
competitive landscape.
Based on test type the
Global Pancreatic Cancer Diagnostics Market can be divided into Diagnostic
Imaging Tests, Biopsy, Blood Tests, Liver Function Tests and Others. Diagnostic
Imaging tests segment is expected to grow in the forecast period with the
largest share in the market. Imaging tests are expected to play a significant
role in the market for pancreatic cancer diagnostics. Imaging tests are
non-invasive and can provide detailed information about the size, location, and
stage of a pancreatic tumor. Computed tomography (CT) scans, magnetic resonance
imaging (MRI) scans, and ultrasound are a few of the imaging procedures that
are frequently used to diagnose pancreatic cancer. These tests use different
technologies to produce detailed images of the pancreas and surrounding
tissues.
Global Pancreatic Cancer Diagnostics Market is
divided into Hospitals & Clinics, Diagnostic Centers, Others based on cancer
type. Hospitals are expected to dominate the market, since they are the primary
site of diagnosis and treatment for pancreatic cancer.
North America, Europe, Asia Pacific, South
America, and Middle East & Africa are the regions into which the Global Pancreatic
Cancer Diagnostics Market can be divided. North America is expected to dominate
the market for pancreatic cancer diagnostics for several reasons. North America
has a well-developed healthcare infrastructure and advanced medical
technologies. The region has many hospitals, diagnostic centers, and research
institutions that are equipped with state-of-the-art diagnostic equipment and
imaging technologies. This infrastructure supports the development and adoption
of innovative pancreatic cancer diagnostic tests, which in turn contributes to
the growth of the market.
Major companies operating in Global Pancreatic Cancer Diagnostics Market are:
·
Siemens Healthcare GmbH
·
FUJIFILM Corporation
·
Laboratory Corporation of America Holdings
·
Abbott Laboratories, Inc.
·
Agilent Technologies, Inc.
·
Thermo Fisher Scientific Inc.
·
Immunovia, Inc.
Download Sample Report
Customers can also request
for 10% free customization on this report.
“The global
pancreatic cancer diagnostics market is poised for significant growth in the
coming years, driven by increasing incidence of the disease and a growing need
for improved diagnostic tools and techniques. While there are challenges the
market will face, such as the difficulty of diagnosing the disease in its early
stages and the high cost of diagnostic tests, innovative companies and
researchers are working hard to develop new and better diagnostic tools that
can improve outcomes for patients with pancreatic cancer.” said Mr. Karan
Chechi, Research Director with TechSci Research, a research based global
management consulting firm.
“Pancreatic
Cancer Diagnostics Market- Global Industry Size, Share, Trends, Opportunity,
and Forecast, 2018-2028, Segmented By Test Type {Diagnostic Imaging Tests (CT
scan, MRI, Ultrasound, Others), Biopsy, Blood Tests, Liver Function Tests,
Others}, By Cancer Type (Exocrine, Adenocarcinoma, Squamous Cell Carcinoma,
Colloid Carcinoma, Others), By End User (Hospitals & Clinics, Diagnostic
Centers, Others), Region and Competition,” has evaluated
the future growth potential of Global Pancreatic Cancer Diagnostics Market
and provides statistics & information on market size, structure, and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Pancreatic Cancer Diagnostics Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web: https://www.techsciresearch.com